Novel glucose-based adsorbents (Glc-As) with preferential adsorption of ethane over ethylene and high capacity
Sign Up to like & getrecommendations! Published in 2017 at "Chemical Engineering Science"
DOI: 10.1016/j.ces.2017.07.020
Abstract: Abstract In this work, we reported novel glucose-based adsorbents (Glc-As) with high C 2 H 6 /C 2 H 4 adsorption capacity and selectivity. Starch sugar (e.g., glucose, 50 wt%) was used as carbon source to… read more here.
Keywords: adsorption; preferential adsorption; novel glucose; glucose based ... See more keywords
Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
Sign Up to like & getrecommendations! Published in 2020 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2020.03.025
Abstract: BACKGROUND Recent randomized control trials have described a protective cardiovascular effect of novel glucose lowering drugs in patients at high cardiovascular risk. Whether these second-line agents have similar effects in the general population is unknown.… read more here.
Keywords: second line; cardiovascular adverse; risk; novel glucose ... See more keywords
Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
Sign Up to like & getrecommendations! Published in 2023 at "Diabetic Medicine"
DOI: 10.1111/dme.15083
Abstract: We investigated evidence from randomised, placebo‐controlled trials of novel glucose‐lowering therapies; sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i), dipeptidyl peptidase‐4 inhibitors (DPP4i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), on physical function in people with type 2 diabetes (T2D). read more here.
Keywords: controlled trials; randomised placebo; novel glucose; glucose lowering ... See more keywords